A major goal of the clinical research on the efficacy of drugs in cancer is to produce well-structured instruments for the evaluation of response to therapy. Response criteria should prove reliable in the assessment of drug effect on the tumor and represent a measure of benefit for the patient. Guidelines to produce reliable measurements of response in solid tumors have been introduced in 2000 (ref. 1) and recently revised by the RECIST working group. 2 In classical Philadelphia-negative (Ph-neg) myeloproliferative neoplasms (MPNs), that is, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), the discovery of JAK2 V617F mutation and other molecular abnormalities has unveiled new targets for therapies and brought to the development of an array of new experimental drugs aimed at modifying the natural history of the diseases. As a consequence, the doctors engaged in clinical research and the industry claiming for drug approval have to face the issue to test new drugs against end points that measure clinically relevant benefits for the patients.
In 2005, the EUMNET consortium produced response criteria for myelofibrosis 3 that were revised in 2006 by the IWG-MRT. 4 Moreover, in 2009, the ELN consortium produced response criteria for ET and PV. 5 Due to the complexity of those disease processes and the absence of measurable tumor mass, different dimensions of response were considered, ranging from decrease of blood cells in peripheral blood, decrease of clinically significant organomegaly, disappearance of disease-related symptoms, improvement of histological bone marrow features, to reduction or disappearance of the molecular signature of the disease. Notwithstanding the use of consensus methodologies for arriving to the production of MPN-specific response criteria, and their multidimensional nature, such definitions of response were not universally applied as primary end points in clinical trials. On the contrary, specifically selected individual target-oriented response criteria were preferred to the standardized response definitions. For example, immunomodulatory drugs for myelofibrosis were tested against response on anemia; 6 anti-JAK2 drugs were tested against reduction of splenomegaly as primary end point. 7 How much the proposed response criteria predict response on clinically relevant outcomes, such as prevention of thrombotic events, prevention of disease transformation into leukemia and disease progression, has been tackled recently by two papers. Hernández-Boluda et al. 8 retrospectively evaluated the criteria of response for ET in 166 patients treated with hydroxyurea for a median of 4.5 years. Overall, 134 patients achieved a complete clinico-hematological response (CR) and 25 a partial response (PR). Patients achieving a CR, even if sustained during the entire follow-up, did not benefit from a lower incidence of thrombosis or an improved survival. The authors concluded that the achievement of response, as defined by the ELN criteria, does not correlate with the patients' outcome. In the paper of Carobbio et al., 9 416 patients with ET treated with hydroxyurea for at least 12 months were retrospectively examined. CR, PR and no response were 25%, 58% and 17%, respectively. After a median follow-up of 3.9 years, 23 deaths, 16 hematologic transformations and 27 thrombotic events were registered. Age, previous thrombosis, leukocytosis, but not ELN responses, were independently associated with higher risk of thrombosis. The actuarial probability of thrombosis was significantly influenced by leukocytosis but not by platelet count, indicating that response on platelet number does not seem of prime relevance in the definition of benefit for patients.
In order to provide guidance in the definition of clinically relevant end points that can expedite new drug approvals for MPNs, the ELN and IWG-MRT groups have launched a new project that will involve experts in the MPN field, industry and FDA/EMA representatives. In a step of the project, a panel of experts in MPNs was selected, and a questionnaire was produced aimed to evaluate how the scientific community felt the value of existing response criteria for the three MPNs with respect to their usefulness as end points of clinical trials for new drugs. A Delphi process (brainstorming, narrowing down and quantification) was applied. 10 The process results are presented in Table 1 . In summary, the panel agreed that the present definitions of response in the three MPNs neither represent a direct measure of benefit for patients nor a comprehensive measure of drug activity. Furthermore, the panel agreed that there is need for improvement of CR criteria in PV and ET, and of overall response criteria in PMF. In the brainstorming phase of the process, suggestions were given on what were the critical points of the current response definitions. The panel agreed on the following suggestions: (a) the response definition in PV and ET should include at least one measure related to myelofibrosis-free survival and thrombosis-free survival; (b) the Letters to the Editor response definitions in the three MPNs should include a patientreported outcome that should reflect a measure of quality of life.
In conclusion, both experimental evidence and experts' opinion pointed out that the current response criteria for MPNs do not capture benefits for patients. This could be one reason why the existing criteria are not universally used as primary end points in clinical trials with new drugs that have biological targets and have the chance to modify the natural history of the disease. Experts in the field claimed that there is an urgent need to modify the existing definitions for CR in ET and PV, and the overall definition in PMF. there are a number of progenitor cell populations in CB that can be differentiated to NK cells. Therefore, CB is a useful source to expand NK cells for adoptive immunotherapy, particularly against malignant cells that express a low level of human leukocyte antigen class I molecules. Resting CB NK cells rapidly respond to cytokine stimulation by increasing cytolytic activity. Adoptive transfer of allogeneic NK cells is a potential immunotherapy to induce a graft-versus-leukemia (GVL) effect, without causing a graft-versus-host disease (GVHD). 3 In this study, we tried to expand NK cells from CB with antileukemic activity using good manufacturing practice (GMP)-compliant substances without feeder cells. We used tacrolimus (FK506) and low molecular Po0.05 and e Po0.05.
